

Barcelona, November 17th 2017

SIGNIFICANT EVENT

Almirall: achievement of \$80 million sales-related milestones from the agreement with AstraZeneca

Almirall, S.A. (“Almirall”), pursuant to article 17 of Regulation (EU) No. 596/2014 on market abuse and article 228 of the restated text of the Securities Market Act approved by the Royal Legislative Decree 4/2015, of 23 October and related provisions, hereby announces that:

We were notified by our partner AstraZeneca of a sales milestone achievement associated with the agreement signed on 1st November 2014 and related to the acclidinium bromide franchise (Bronchodilator treatment to relieve the symptoms of chronic obstructive pulmonary disease, COPD). This represents an amount of \$80 million expected to be paid in December 2017.

With the recent positive Phase III studies for the registration of acclidinium + formoterol combination in the US, we remain positive about this partnership and associated potential future milestones.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations & Corporate Comms. Department
investors@almirall.com